Elderly patients: NBTXR3 as a novel treatment option in locally advanced HNSCC

ASTRO, San Antonio, Texas · 2018, V. Calugaru et al.

Authors

V. Calugaru1, C. Hoffmann1, V. Moreno Garcia2, X. Mirabel3, B. Dodger2, E. Calvo2, T. Jouffroy1, J. Rodriguez1, A. Chilles1, M. Yemi1, M. Lesnik1, N. Badois1, X. Liem3, C. Le Tourneau1

1 – Institut Curie, Paris, France
2 – START Madrid, Madrid, Spain
3 – Centre Oscar Lambret, Lille, France

Summary

As the incidence of head and neck squamous cell carcinoma (HNSCC) increases with age, elderly patients represent 25% of the affected population with an expected increase in the next 20 years. Being more vulnerable to treatment-induced toxicities, the elderly cannot be treated like younger patients, hence requiring innovative therapies.

A new treatment option is currently clinically evaluated, NBTXR3. These first-in-class hafnium oxide nanoparticles are activated by radiotherapy and can physically destroy cancer cells. A phase I study [NCT01946867] was implemented for the treatment of locally advanced HNSCC of the oral cavity and oropharynx, focused on elderly patients (65 years and older) not eligible for cisplatin, the non-surgical standard of care, or intolerant to cetuximab. Even at the highest doses, NBTXR3 is associated with a positive safety profile. Recruitment in the fourth and last dose level at 22% is ongoing.

Preliminary results tend to highlight NBTXR3 benefit as a novel treatment option for elderly patients in locally advanced HNSCC. Considering the challenges brought by the population of interest, this study could lead to new perspectives in the support of frail patients with advanced age. This study answers a major medical need, as most HNSCC clinical trials do not focus on elderly patients.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer